Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~healthy female and male subjects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BI 10773 (Type: EXPERIMENTAL): single oral (high and low) dose per subject
- Placebo (Type: PLACEBO_COMPARATOR): 2 single oral doses per subject
- Moxifloxacin (Type: ACTIVE_COMPARATOR): single oral dose per subject

Based on this trial design, predict the completion outcome and termination type (if applicable).